{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-037944","form_type":"8-K","ticker":"MEDP","cik":"0001668397","company_name":"Medpace Holdings, Inc.","filed_at":"2021-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.094910+00:00","generated_at":"2026-06-30T02:37:26.408612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medpace Q2 2021 revenue up 35.8% to $278.3M; net income $39.9M ($1.06 EPS)","bullets":["Net new business awards of $387.6M (+52.5% YoY) produced a 1.39x book-to-bill ratio.","Backlog grew 29.8% to $1.7B; revenue backlog conversion rate 17.1%.","EBITDA $47.9M (17.2% margin), up 36.9% YoY; GAAP net income margin 14.3%.","Direct costs $203.6M vs $148.4M; SG&A $27.0M vs $21.9M in prior-year quarter.","On a constant currency basis, organic revenue grew 34.4% and EBITDA grew 41.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-037944","json":"https://secwatch.observer/filing/0001564590-21-037944.json","markdown":"https://secwatch.observer/filing/0001564590-21-037944.md","text":"https://secwatch.observer/filing/0001564590-21-037944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668397/000156459021037944/0001564590-21-037944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668397/000156459021037944/medp-8k_20210726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T02:37:26.408612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}